The results of a Phase II randomized trial of cisplatin in the presence/absence of veliparib in metastatic TNBC and/or germline BRCA-associated breast cancer (Swog S1416) demonstrated superior progression-free survival (PFS) with PARP inhibitor monotherapy compared with chemotherapy for gBRCA mutation [57]. This evidence concerns the gene PARP1 and breast carcinoma.